Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Philip Sarges

Gastroenterology Grand Junction, CO Medical Doctor

NPI 1538393939 CMS profile 1381713

1035 Wellington Ave, Grand Junction, CO 81501

Open in the dashboard

General payments

$8,773

376 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Philip Sarges of Grand Junction, CO is reported in the CMS Open Payments database as having received $8,773 across 376 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,741 65
2024 General $2,222 83
2023 General $1,593 63
2022 General $1,012 49
2021 General $621 35
2020 General $282 18
2019 General $1,303 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philip Sarges
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Philip Sarges were reported at $1,741. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Philip Sarges Gastroenterology median Middle half National median
2019 $1,303 $417 $126–$1,100 $163
2020 $282 $224 $74–$624 $114
2021 $621 $352 $106–$1,054 $132
2022 $1,012 $448 $129–$1,270 $149
2023 $1,593 $533 $150–$1,390 $160
2024 $2,222 $605 $160–$1,606 $164
2025 $1,741 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,950 147 payments
  2. Gilead Sciences, Inc. $851 42 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $788 40 payments
  4. Janssen Biotech, Inc. $505 24 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $397 20 payments
  6. Pfizer Inc. $372 20 payments
  7. Intercept Pharmaceuticals, Inc. $239 8 payments
  8. Ardelyx, Inc. $227 7 payments
  9. Regeneron Healthcare Solutions, Inc. $222 10 payments
  10. Phathom Pharmaceuticals, Inc. $206 5 payments
  11. Other $1,014 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,723 373 payments
  2. Education $50 3 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,406 53 payments
  2. SKYRIZI Immunology $1,127 29 payments
  3. HUMIRA $745 38 payments
  4. ENTYVIO $589 29 payments
  5. SKYRIZI Immunology $457 14 payments
  6. XIFAXAN $386 19 payments
  7. STELARA $332 17 payments
  8. MAVYRET $301 20 payments
  9. XELJANZ $242 18 payments
  10. CREON $228 14 payments
  11. Other $3,177 146 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

503

Median for Gastroenterology: 569

Drug cost

$247,615

Median for Gastroenterology: $104,976

Branded share of claims

25.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 23 $160,536
Creon Lipase/Protease/Amylase Brand 15 $36,975
Mesalamine Generic 31 $16,311
Linzess Linaclotide Brand 21 $15,402
Dexlansoprazole Dr Dexlansoprazole Brand 23 $10,017
Budesonide Dr Budesonide Brand 37 $2,602
Omeprazole Generic 177 $1,967
Budesonide Ec Budesonide Brand 11 $1,254
Dicyclomine Hcl Generic 53 $928
Pantoprazole Sodium Generic 45 $552

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$109,733

Medicare's payments for the services billed

Medicare patients

478

Average age 73

Services billed

846

243 women, 235 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 40%
Diabetes 22%
Ischemic heart disease 19%
Depression 19%
Osteoporosis 17%
Atrial fibrillation 15%
Chronic kidney disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $522
$522 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $264
$264 — —
RINVOQ
  • AbbVie, Inc. $222
$222 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $172
$172 — —
VELSIPITY
  • PFIZER INC. $146
$146 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

376 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record